Abstract
Neurodegenerative diseases (NDs) are some of the most debilitating human illnesses. Research over the past 10 years has pro-vided evidence for a common mechanism of neurodegeneration in which the critical event is the brain accumulation of misfolded protein aggregates. Although it is well established that misfolded proteins play an important role in these diseases, the mechanisms by which they cause cellular and tissue dysfunction are still unknown. To understand the molecular basis of NDs and to develop therapeutic strategies against them, numerous transgenic rodent models have been produced, which reproduce some (but not all) of the features of these dis-eases. Importantly, some NDs are not exclusive to human beings, such as transmissible spongiform encephalopathies. Moreover, other diseases which are associated to aging (e.g. Alzheimers disease) could be studied in aged mammals, which could reproduce the human disease in a more natural way. Although the usefulness of transgenic mice is unquestio nable, the information obtained from natural non-transgenic models could be very valuable to fully understand the pathogenesis of these devastating diseases.
Keywords: Prion, protein misfolding, natural model, non-transgenic, Alzheimer's disease, amyloid, Neurodegenerative diseases (NDs), aging, transgenic mice, transmissible spongiform encephalopathies
Current Pharmaceutical Design
Title: Natural Animal Models of Neurodegenerative Protein Misfolding Diseases
Volume: 18 Issue: 8
Author(s): Ines Moreno-Gonzalez and Claudio Soto
Affiliation:
Keywords: Prion, protein misfolding, natural model, non-transgenic, Alzheimer's disease, amyloid, Neurodegenerative diseases (NDs), aging, transgenic mice, transmissible spongiform encephalopathies
Abstract: Neurodegenerative diseases (NDs) are some of the most debilitating human illnesses. Research over the past 10 years has pro-vided evidence for a common mechanism of neurodegeneration in which the critical event is the brain accumulation of misfolded protein aggregates. Although it is well established that misfolded proteins play an important role in these diseases, the mechanisms by which they cause cellular and tissue dysfunction are still unknown. To understand the molecular basis of NDs and to develop therapeutic strategies against them, numerous transgenic rodent models have been produced, which reproduce some (but not all) of the features of these dis-eases. Importantly, some NDs are not exclusive to human beings, such as transmissible spongiform encephalopathies. Moreover, other diseases which are associated to aging (e.g. Alzheimers disease) could be studied in aged mammals, which could reproduce the human disease in a more natural way. Although the usefulness of transgenic mice is unquestio nable, the information obtained from natural non-transgenic models could be very valuable to fully understand the pathogenesis of these devastating diseases.
Export Options
About this article
Cite this article as:
Moreno-Gonzalez Ines and Soto Claudio, Natural Animal Models of Neurodegenerative Protein Misfolding Diseases, Current Pharmaceutical Design 2012; 18 (8) . https://dx.doi.org/10.2174/138161212799315768
DOI https://dx.doi.org/10.2174/138161212799315768 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology
Current Pharmaceutical Design Brain Structural Effects of Antidepressant Treatment in Major Depression
Current Neuropharmacology Improvement of Microscopic MR Imaging of Amyloid Plaques with Targeting and Non-Targeting Contrast Agents
Current Medical Imaging Pharmacotherapy and Prevention of Vascular Dementia
CNS & Neurological Disorders - Drug Targets The Development of Topically Acting Carbonic Anhydrase Inhibitors as Antiglaucoma Agents
Current Pharmaceutical Design The Interactions Between Alzheimer’s Disease and Major Depression: Role of Ca<sup>2+</sup> Channel Blockers and Ca<sup>2+</sup>/cAMP Signalling
Current Drug Research Reviews The Role of Lipids and Membranes in the Pathogenesis of Alzheimer's Disease: A Comprehensive View
Current Alzheimer Research Conference Report: 14th International Congress on Amino Acids, Peptides and Proteins, Vienna, Austria, August 3-7, 2015
CNS & Neurological Disorders - Drug Targets Depot Based Drug Delivery System for the Management of Depression
Current Drug Delivery Breaking the Barrier in Stroke: What Should we Know? A Mini-Review
Current Pharmaceutical Design Synthesis of Novel 1-benzhydryl-4-(3-(piperidin-4-yl)propyl) Piperidine Sulfonamides as Anticonvulsant Agents
Letters in Drug Design & Discovery Nature and Nurture: Genetic Influences and Gene-Environment Interactions in Depression
Current Psychiatry Reviews Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Commentary: Toward a Personalized Medicine in Wake-Up Stroke?
CNS & Neurological Disorders - Drug Targets Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Alzheimer’s Disease-like Early-phase Brain Pathogenesis: Self-curing Amelioration of Neurodegeneration from Pro-inflammatory ‘Wounding’ to Anti-inflammatory ‘Healing’
Current Alzheimer Research Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Contemporary Risk Assessment and Cardiovascular Outcomes in Peripheral Arterial Disease
Cardiovascular & Hematological Disorders-Drug Targets Do Geriatric Outpatients Adhere to Medication Changes Advised After Assessment? An Exploratory Pilot Study
Current Clinical Pharmacology